Immunoglobulin G

POLIVY (Polatuzumab Vedotin-piiq) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Biotechnology, General Health, Pharmaceutical, Health, MMAE, Apoptosis, Research, Immunoglobulin G, ADC, Clinical trial, SWOT, EU4, Microtubule, Polatuzumab vedotin, Roche, CD79B, Cell division, NHL, Fine chemical, Risk management, Vaccine, Pharmaceutical industry, DLBCL

This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the POLIVY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • What are the other emerging products available and how are these giving competition to POLIVY for DLBCL?

Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​

Retrieved on: 
Sunday, December 10, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Partial thromboplastin time, Safety, Haemophilia, Food, HDR, Engineering, Plasma, Hematology, Bio-MEMS, Mortality, CCR5, Mouse, Multimedia, BCMS, PCR, Defence Scientific Advisory Council, World government, WFH, FIX, Committee, Availability, Investigational New Drug, World Federation of Hemophilia, Factor IX, Human services, Cas9, Bleeding, Person, Pain, Drug discovery, American Society of Hematology, DdPCR, Coronavirus Scientific Advisory Board, Society, Cell, BCM, Real-time, AAV, ELISA, Immunoglobulin G, Therapure BioPharma Inc, Pharmaceutical industry, Vaccine

“We are excited by these findings as we advance this novel BCM into clinical development to address enduring unmet medical needs for people living with hemophilia B.

Key Points: 
  • “We are excited by these findings as we advance this novel BCM into clinical development to address enduring unmet medical needs for people living with hemophilia B.
  • Many people living with hemophilia B still experience bleeding episodes, irreversible joint damage and pain with current extended-release factor IX biologic therapy.
  • “Our goal is to create a new, potentially transformative treatment option that will provide people with hemophilia B the freedom to live a normal life, free of limitations from hemophilia B.
  • The data confirmed the expected biodistribution of FIX-expressing BCMs in bone marrow tissue, where they engraft stably over time.

MBrace Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Antibody Drug Conjugate at 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 7, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, MMAE, MBrace, Safety, Research and development, New Jersey Medical School, Spacecraft, Therapy, Annexin A5, Immunoglobulin G, ADC, HED, Breast cancer, Teaching hospital, Patient, TNBC, Division, Laboratory, Breast, Cancer, Professor, Cell, Cooper University Hospital, HR, Medical imaging

MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.

Key Points: 
  • MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.
  • In the data presented today, robust and selective EphA5 expression was detected in greater than 80% of triple negative breast cancer (TNBC) and greater than 80% of HR+ breast cancer tissue samples.
  • EphA5 expression was not detected in adjacent, non-malignant breast tissue or normal breast.
  • Details of the poster presentation are as follows:
    Presenter: Fernanda Staquicini, Ph.D., Director of Research & Development, MBrace Therapeutics

Ability Biologics Unveils Discovery Platform that Generates Antibodies with Unparalleled Specificity and Selectivity

Retrieved on: 
Wednesday, December 6, 2023
Stem Cells, Biotechnology, Health, Artificial Intelligence, Health Technology, Technology, Genetics, Other Health, Engineering, Tissue, Artificial intelligence, CFA, Investment, Charles River Laboratories, Laboratory, FTQ, Therapy, Drug discovery, Private equity, Partnership, Antibody, AI, Fonds, Cell, Temperature, Drug development, Immunoglobulin G, Pharmaceutical industry, Fine chemical, Ability

Ability Biologics (“Ability” or “the company”) announced the closing of its $12 million (US) financing round led by founding investor Amplitude Ventures .

Key Points: 
  • Ability Biologics (“Ability” or “the company”) announced the closing of its $12 million (US) financing round led by founding investor Amplitude Ventures .
  • Ability Biologics will use its AbiLeap™ discovery engine to systematically generate logic-enabled antibodies with the potential to become best-in-class or first-in-class therapeutics.
  • Their vision is to create the next generation of antibodies using powerful computational tools through its unique, proprietary AI platform.
  • Ability is establishing its laboratories in Montreal, which is emerging as a fast-paced R&D hub in key areas such as biologics, antibodies, and AI.

Avilar Therapeutics Receives U.S. Patent for Novel Extracellular Protein Degraders

Retrieved on: 
Monday, November 27, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, ATAC, Creativity, Therapy, Asialoglycoprotein receptor, Protein, ATACS, Patent, Immunoglobulin G, Ligand

Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced that the U.S. Patent and Trademark Office issued U.S. Patent 11,819,551 on November 21, 2023.

Key Points: 
  • Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced that the U.S. Patent and Trademark Office issued U.S. Patent 11,819,551 on November 21, 2023.
  • The issued patent provides broad protection for Avilar’s first wave of extracellular proteins degraders called ATACs (ASGPR Targeting Chimeras) with therapeutic applications in a wide range of human diseases.
  • “This patent underscores the creativity and expertise of Avilar scientists, who conceived and developed new and improved ASGPR ligand chemistry.
  • The resulting novel ligands provide the backbone for Avilar’s ATAC extracellular degraders and offer advantages versus previous approaches, including our ability to achieve high levels of protein degradation using lower molecular weight monovalent compounds.”
    Avilar has successfully demonstrated in vivo proof-of-concept for ATACs as potent degraders of extracellular proteins.

Longhorn Vaccines and Diagnostics Presents Targeted Vaccine Approach for Mycobacterium Tuberculosis with LHNVD-301

Retrieved on: 
Wednesday, November 15, 2023
Science, Veterinary, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Pandemic, Peptide, MTB, Lung, Safety, Peptidoglycan, The Union, Serum, PGN, Immunoglobulin G, Risk, Gram-positive bacteria, Epitope, Staphylococcus aureus, ELISA, Infection, Staphylococcus, Staphylococcus epidermidis, Vaccine, Mycobacterium tuberculosis, Bacillus subtilis, Cell wall, AMR, Conference, Streptococcus, Virus, Antibody, Bacilli, Mycobacterium smegmatis, Tuberculosis, Public, TB, ICR, Bacteria, Longhorn, MD

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.
  • The data showed that a mycobacterium tuberculosis (MTB) vaccine could generate broader protection against other pathogens susceptible to antimicrobial resistance (AMR).
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines a MTB heat shock protein epitope and a peptidoglycan (PGN) epitope.
  • It represents a novel approach that combats AMR, while targeting tuberculosis by combining multiple epitopes specific to MTB and common to gram-positive bacteria into a peptide vaccine.

Reverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokines 

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Professional Services, Health, Philanthropy, General Health, Pharmaceutical, Oncology, Other Philanthropy, Research, Science, Finance, Amplifier, Multiple myeloma, Cytokine, School, Preamplifier, Alexion, AstraZeneca, Therapy, Toxicity, University of British Columbia, Boehringer Ingelheim, Risk, Flagship Pioneering, CSO, MMRF, Patient, Systems biology, Element, SAB, Amplitude, University, Antibody, Zymeworks, Cancer, Neoplasm, Harvard University, Biomedical engineering, Cell, Immunoglobulin G, Vaccine, Management, Pfizer, Reverberation

Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .

Key Points: 
  • Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .
  • Reverb Therapeutics is advancing its novel antibody-based AmplifierTM platform to treat a broad range of diseases with endogenous cytokines that naturally occur within the body.
  • Instead of using heavily engineered exogenous cytokines to treat disease—which have consistently presented challenges such as systemic toxicity, immunogenicity and challenging production requirements—Reverb’s antibodies redirect endogenous, natural cytokines to cells of interest.
  • “We are keenly aware of the clinical obstacles to more widespread use of exogenous cytokines to treat patients,” said David de Graaf, Ph.D., Co-founder and CEO of Reverb Therapeutics.

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunoglobulin G, ASN, PMN, UPCR, Investment, Clinical trial, American Society of Nephrology, APRIL, Glomerular filtration rate, Administration, Patient, TACI, Inflammation, Immunoglobulin A, Neonatal Fc receptor, Lupus, Infection, Research program, BAFF, SLE, ALPN, Immunoglobulin M, MD, Development, EGFR, BCMA, Society, NIH Intramural Research Program, Autoimmunity, Proteinuria, AANEM, Pharmaceutical industry, Sewage treatment, Vaccine, Paint, IgA nephropathy, AbbVie, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.
  • “Following our data presentation, we executed a follow-on equity offering of $150 million to bolster our balance sheet.
  • Cash Position and Runway: As of September 30, 2023, Alpine’s cash and investments totaled $227.2 million compared to $273.4 million as of December 31, 2022.
  • The respective increases of $0.8 million and $2.3 million were primarily attributable to increases in personnel and legal costs.

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Other Science, Science, Safety, D, Pharmaceutical industry in Switzerland, Therapy, TED, IND, Investment, Patient, Neonatal Fc receptor, LDL, Conditional sentence, Pharmacokinetics, Half-life, Immunoglobulin G, Intravenous therapy, Pharmaceutical industry, Management, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.
  • The ongoing THRIVE Phase 3 clinical trial of VRDN-001 in patients with active TED continues to enroll patients with topline results expected in mid-2024.
  • Net Loss: The company’s net loss was $47.7 million for the third quarter of 2023, compared with $28.9 million for the same period last year.
  • Viridian will not be hosting a conference call to discuss its third quarter financial results.

Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Genetics, Health, Clinical Trials, Gene, Rheumatology, Patient, Inflammation, Synergy, Lupus, American College, CD28, SLE, ALPN, CD80, Alpine, ICOS, Autoimmunity, Immunoglobulin G, CD86, Pharmaceutical industry, Vaccine, Research

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
  • Acazicolcept target-related genes (ICOS, CD80, CD86) are upregulated in the T and B cells of SLE patients compared to healthy adults.
  • Acazicolcept reduces pathogenic hypergammaglobulinemia and glomerular IgG deposition in a mouse model of lupus.
  • Clinical investigation of acazicolcept for the treatment of SLE, such as in our ongoing phase 2 study, Synergy, continues to be supported.”